Background-Previously, we showed that a mouse model (ACE8/8) of cardiac renin-angiotensin system activation has a high rate of spontaneous ventricular tachycardia and sudden cardiac death secondary to a reduction in connexin43 level. Angiotensin-II activation increases reactive oxygen species (ROS) production, and ACE8/8 mice show increased cardiac ROS. We sought to determine the source of ROS and whether ROS played a role in the arrhythmogenesis. 
A n increased level of angiotensin-II (AngII), as is found in heart failure, is associated with an increased risk of ventricular tachycardia (VT), and treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduces that risk. 1 Investigating the mechanisms of AngIIinduced arrhythmia may result in finding new antiarrhythmic targets. We created a mouse model of cardiac-restricted angiotensin-converting enzyme overexpression. We demonstrated that homozygous mice (ACE8/8) have a high rate of sudden cardiac death (SCD), with telemetry monitoring showing that ≈80% of the SCD resulted from VT and less commonly severe bradycardia and conduction block, in the absence of any left ventricular structural or functional abnormality at the studied age. 2 The VT and bradycardia were the result of c-Src tyrosine kinase activation, connexin43 (Cx43) reduction, and the impairment of gap junction conduction.
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AngII is known to increase reactive oxygen species (ROS) levels. 4 Excess amounts of ROS have been implicated in the genesis of arrhythmia, 2, 5, 6 and ROS is known to activate c-Src. 7 Nevertheless, there is no clear proof that oxidative stress causes arrhythmia or of how oxidative stress might contribute to the arrhythmic substrate. Therefore, we sought to determine whether ROS mediated any of the Cx43 remodeling during renin-angiotensin system (RAS) activation and the principal source of cardiac ROS responsible for arrhythmic risk. Sources of ROS include the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase that generally requires the p67 subunit for activity, xanthine oxidase, uncoupled NO synthase (NOS) in part because of tetrahydrobiopterin depletion, and mitochondria. 8 We inhibited each source in turn using previously established methods [9] [10] [11] [12] [13] [14] [15] and explored the effect on RAS-induced arrhythmogenesis.
Materials and Methods
The animal experiments were performed according to the National Institutes of Health Guide for the Care and Use of Experimental Animals and were approved by the University of Illinois Institutional Animal Care and Use Committee. All mice in this study were started on treatment at the age of 4 weeks, and they were studied for 2 weeks. In our previous studies of ACE8/8 mice, we did not detect any difference in the phenotypes based on the mouse sex.
2,3 Therefore, we used both sexes for our experiments. A group of wild-type mice (n=10), with similar background to the ACE8/8 mice (C57BL), and the following groups of ACE8/8 mice were studied: In addition, a group of wild-type mice were treated with MitoTEMPO (0.7 mg/kg per day intraperitoneal injections for 2 weeks, n=5) to evaluate for any possible harmful effects of treatment. Figure 1 . A mitochondrial antioxidant inhibits sudden cardiac death and ventricular arrhythmia inducibility. A, Renin-angiotensin system activation mice were treated with the following antioxidants: apocynin, L-NIO, sepiapterin, allopurinol, TEMPOL, and MitoTEMPO. A group of ACE8/8 mice were also crossed with P67DN mice. Kaplan-Meier survival analysis and log-rank tests show significant improvement in the survival free from sudden arrhythmic death only in the ACE8/8 mice that were treated with MitoTEMPO . MitoTEMPO had no effect on wild-type mice (WT). B, Representative electrocardiograms (ECG lead II) and right ventricular electrograms (endocardial EGM) of WT, ACE8/8, and ACE8/8 mice treated with MitoTEMPO are shown. Ventricular tachycardia (VT) was induced in 90% of ACE8/8 mice (9 of 10) using a burst pacing protocol starting at 100 ms pacing cycle length (PCL) and decreasing to 30 ms PCL or 2:1 capture. Treatment with MitoTEMPO reduced VT inducibility in ACE8/8 mice to 17% (1 of 6 mice) using the above pacing protocol (P<0.05).
Survival Recording and Analysis
Survival of all treated and untreated groups were recorded every morning during the 2 weeks of treatment and observation. Survival was assessed by using Kaplan-Meier analysis and log-rank tests.
Telemetry Monitoring
Please see Methods in the online-only Data Supplement.
Electrophysiology Study
For the electrophysiology studies, the control mice (n=5), ACE8/8 mice (n=10), and ACE8/8 mice treated with MitoTEMPO (n=6) were studied as previously described (see Methods in the online-only Data Supplement). 
Mitochondrial ROS Measurement by Confocal Microscopy
To measure mitochondrial ROS, the fluorescent probe MitoSOX Red was used as previously described. 16 Cardiomyocytes were isolated from control, ACE8/8 mice, or ACE8/8 mice treated with MitoTEMPO (n=3 for each group; see Methods in the online-only Data Supplement).
Mitochondrial ROS Measurement by Flow Cytometry
To quantify the mitochondrial ROS by flow cytometry, the measurements were performed using a CyAn ADP Analyzer (Beckman Coulter, Brea, CA). Isolated cardiomyocytes from each group (n=3 animals for each group) were stained with 5 µmol/L MitoSOX Red with a similar method as above (see Methods in the online-only Data Supplement).
Transmission Electron Microscopy
The control, ACE8/8 mice, and ACE8/8 mice treated with MitoTEMPO were studied (n=3 for each group; see Methods in the online-only Data Supplement).
Western Blot Analysis
The control, ACE8/8 mice, and ACE8/8 mice treated with MitoTEMPO (n=5 for each group) were euthanized, and their hearts were excised (see Methods in the online-only Data Supplement).
Immunohistochemistry
The control, ACE8/8, and ACE8/8 treated with MitoTEMPO mouse hearts (n=4 for each group) were fixed in 10% formalin. After which, 8-μm thick sections were blocked for 1 hour at room temperature and then were incubated with anti-Cx43 antibodies (Cell Signaling) overnight at 4°C at concentrations known to provide the best signal-tonoise ratio. This method has been used previously to quantify levels of collagen and Cx43 in cardiac tissue (see Methods in the onlineonly Data Supplement).
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Functional Assessment of Cx43
We used an established technique for measuring Cx43 function that involves fluorescent dye introduction and diffusion in intact heart muscle (see Methods in the online-only Data Supplement).
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Statistical Analysis
The values are presented as the mean±SEM. The t test was used to evaluate the statistical significance between 2 groups for analysis of the mitochondrial ROS measurement, Western blot, immunohistochemistry, and electron microscopy results. One-way ANOVA with post hoc Tukey honestly significant test was used to evaluate the statistical significance among the groups for the analysis of the dye diffusion test. The Fisher exact test for 2×2 tables was used for analysis of the VT inducibility by electrophysiology tests. A P value of <0.05 was reported as statistically significant. The survival data were analyzed with the Kaplan-Meier method, and the P value was calculated with the log-rank test. In the in vivo electrophysiology studies, VT was induced in 90% (9 of 10) of ACE8/8 mice using a burst pacing protocol with a mean pacing cycle length of 44 ms. The induced VTs in the ACE8/8 mice were primarily monomorphic (88%). VT inducibility in ACE8/8 mice was decreased from 90% to 17% (1 of 6) by MitoTEMPO treatment (P<0.05; Figure 1B ). VT could not be induced in control mice.
MitoTEMPO Treatment Reduced Mitochondrial Superoxide Levels
Quantification of mitochondrial ROS levels by the MitoSOX reduction and flow cytometry methods revealed a 1.5-fold increase in the mitochondrial superoxide level in the ACE8/8 mice compared with the control mice (P<0.05; Figure 2A ). MitoTEMPO treatment reduced mitochondrial ROS level to 1.1-fold of that in the control mice (P=0.45; Figure 2A ). Quantification of mitochondria by MitoTracker Green did not show any significant change between those groups ( Figure 2B ).
MitoTEMPO Reversed Mitochondrial Damage in RAS Activation
By electron microscopy, the percentage of the cytoplasmic area occupied by mitochondria was not statistically different among the groups studied, consistent with mitochondria quantification with MitoTracker Green (Figure 3 ). Nevertheless, ACE8/8 mice showed significant damage to the mitochondria inner membrane and cisterna ( Figure 3 ; Figure II in the online-only Data Supplement). The damaged area identified by the ratio of vacuous area within a mitochondrion to the whole mitochondrion was significantly higher in the ACE8/8 than in the control mice. This ratio was ameliorated by MitoTEMPO treatment (6.5±3%, 15±4%, and 8.5±3% in the control, the ACE8/8, and the ACE8/8 mice treated with MitoTEMPO, respectively; P<0.05 for control compared with ACE8/8 mice). Although mitochondria morphology was improved with 2 weeks of MitoTEMPO treatment, we did not study the time course or durability of the improvements in this study. Rarely could gap junctions be identified in untreated ACE8/8 cardiomyocytes, but gap junctions could be easily identified in the control and treated groups. Histological analysis and annexin V staining showed no differences in necrosis or apoptosis between treated and untreated groups accompanying these structural changes in mitochondria.
MitoTEMPO Increased Cx43 Levels at the Gap Junctions
The total Cx43 level detected by Western blot was decreased in ACE8/8 mice to 24% of control (P<0.05), and Mito-TEMPO treatment increased that to 62% of control (P<0.05; Figure 4A ). By immunohistochemistry, Cx43 level in ACE8/8 mice was decreased at intercalated disks to a comparable level measured by Western blot, and most of the remaining Cx43 in the untreated ACE8/8 mice was no longer located at identifiable intercalated disks ( Figure 4B ). Cx43 increased significantly after MitoTEMPO treatment (P<0.05). Src is known to displace Cx43 from the intercalated disk, 19 and the level of active c-Src, phospho-(Tyr416), was 32% higher in ACE8/8 than in control mouse hearts. Phospho-Src was reduced to that of control mice by MitoTEMPO treatment (P=0.29 compared with control; Figure II in the online-only Data Supplement).
MitoTEMPO Increased Gap Junction Conduction to the Control Level
To determine whether changes in Cx43 levels resulted in functional changes in gap junction conduction at the whole heart level, an established method of fluorescent dye diffusion was used ( Figure 5 ). The predominant effect of MitoTEMPO on improving the dye diffusion longitudinally was consistent with the improvement of Cx43 level at the gap junctions in immunostaining experiments. The gap junction dye diffusion in the longitudinal direction was reduced in untreated ACE8/8 mice to 62% of that in the control mice (P<0.05). MitoTEMPO treatment returned the gap junction conduction to the normal range (P=0.97 compared with control).
Discussion
Cx43 is the major structural protein of ventricular gap junctions, and a significant decrease in Cx43 causes sudden arrhythmic death. 20 In this study, we showed that cardiac RAS activation, as occurs in heart failure, 1, 21 was associated with a significant reduction in Cx43. This range of reduction in Cx43 is known to be arrhythmogenic. 22 These experiments establish that AngII-mediated ROS plays a role in ventricular arrhythmogenesis, that the mitochondria are the principal source of ROS leading to the arrhythmic substrate, and that ROS is arrhythmogenic, at least in part, by altering Cx43 probably by ROS activation of c-Src. 23, 24 Although ROS have been implicated in the genesis of arrhythmia, [25] [26] [27] [28] [29] translation of those findings to clinical studies using general ROS scavengers, such as vitamin E and C, has not produced impressive results. 30 In our study, only a mitochondria-targeted antioxidant was able to prevent arrhythmia. Targeting other known cardiac sources of ROS or using a general antioxidant was ineffective despite dosages and routes of administration that have been shown to be effective in inhibition of the targeted source of ROS production. [9] [10] [11] [12] [13] [14] [15] This result, particularly the therapeutic difference between TEMPOL and MitoTEMPO treatments, suggests that AngII-mediated ROS production is highly compartmentalized within mitochondria in cardiomyocytes.
It has been recently shown that AngII receptors exist on the mitochondrial inner membrane, 31 and that AngII may affect directly mitochondrial ROS production. In addition, an isoform of the NADPH oxidase (NOX4) exists in mitochondria, 32, 33 and AngII is known to activate NADPH oxidase. 34, 35 Although our experiments do not suggest a role for the conventional NADPH oxidase, NOX4 does not require the P67 subunit for its activation, 36 and apocynin may not effectively inhibit mitochondrial NOX4-dependent ROS production. Therefore, it is possible that this system could be involved in what seems to be AngII signaling directly to mitochondria, possibly through a ROS-induced-ROS mechanism. 37 Our study does not preclude the possibility of other sources of ROS contributing to arrhythmogenesis in other cardiac pathological states. The RAS activation model used leaves open the possibility that inhibition of other sources of ROS could be effective in more complicated disease states. Moreover, it has been shown that perfusion of the whole heart or isolated cardiomyocytes with H 2 O 2 is arrhythmogenic, which highlights the importance of the amount of ROS production in arrhythmogenesis, independent of the source of ROS. 26 Consistent with other reports, 5 we found that >30% of the cardiomyocyte area was occupied by mitochondria, and these mitochondria were producing 1.5× higher superoxide in RAS activation mice than in control mice. Therefore, our results may simply be a function of the relative amounts of the enzymatic ROS sources in a cardiomyocyte. Similar findings of the importance of mitochondria as a source of ROS and accompanying mitochondrial damage were recently reported in other cardiac pathologies, such as heart failure, a RAS activation state. 5, 38, 39 These results may have clinical implications in patients with heart failure because AngII and ROS are elevated in that condition. 1, 21, [40] [41] [42] [43] Cx43 is reduced in heart failure, and sudden death is increased. 44, 45 Our findings collectively can be explained by a signaling cascade where cardiac RAS activation increases mitochondrial ROS production and mitochondrial injury, activates c-Src, reduces Cx43 at intercalated disks through competition with activated c-Src, reduces gap junction function, and increases ventricular arrhythmias ( Figure 6 ). This proposed signaling cascade could explain why angiotensin-converting enzyme inhibitors and AngII receptor blockers decrease sudden death. 1, 41 In addition, these results may have clinical implications in pathological conditions with elevated levels of ROS and c-Src activation exclusive of AngII, for example, in cardiac ischemia and in ischemia-reperfusion state.
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Limitations
Cardiac-restricted elevation of AngII in this model without hypertension, and systolic dysfunction allowed investigation of the direct arrhythmogenesis effects of AngII in the heart. Although it is not generally expected, the results may vary in systemic elevation of AngII. It is also possible that MitoTEMPO exerted part of its antiarrhythmic effects by mechanisms other than c-Src activation and Cx43 remodeling. On the contrary, the lack of ventricular fibrosis, normal cardiac sodium current, and an unchanged ventricular effective refractory period in the ACE8/8 mice at the age they were studied support a major role for mitochondrial ROS in RAS-mediated Cx43 remodeling. 2, 3, 47, 48 Although the major effect of MitoTEMPO treatment seemed to increase the amount of Cx43, MitoTEMPO treatment also seemed to increase Cx43 phosphorylation, which may help explain the improvement noted in connexon function. The reason for the early mortality in the MitoTEMPO treated mice is unknown, but it is possible that antioxidant treatment takes several days to reach maximum effect. Because treatments were not continued for >2 weeks, it is unclear whether MitoTEMPO treatment prevented sudden death or simply delayed it.
Conclusions
In summary, we found that RAS activation resulted in mitochondrial injury, mitochondrial ROS production, reduction in Cx43, and increased arrhythmic risk. These changes were ameliorated by a mitochondria-targeted antioxidant but not agents targeted to other sources of cardiac oxidation or a general antioxidant. These results establish that ROS can be arrhythmogenic and elucidate a possible mechanism, whereby ROS can cause arrhythmia.
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